Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)
Fibrinogen to Albumin Ratio as a Predictive Biomarker for Lupus Nephritis (LN)
1 other identifier
observational
90
0 countries
N/A
Brief Summary
Fibrinogen to Albumin ratio as a predictive biomarker for lupus nephritis (LN)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 12, 2023
CompletedFirst Posted
Study publicly available on registry
March 1, 2024
CompletedStudy Start
First participant enrolled
March 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedMarch 1, 2024
February 1, 2024
8 months
November 12, 2023
February 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Fibrinogen to Albumin ratio as a predictive biomarker for lupus nephritis (LN)
investigate the association of fibrinogen to albumin ratio (FAR) with LN and to prove its possible role as a novel biomarker to predict LN progression
1 year
Interventions
To investigate the association of fibrinogen to albumin ratio (FAR) with LN in different classes. b. Secondary (subsidiary): To prove the possible role of FAR as a novel diagnostic biomarker to predict LN progression
Eligibility Criteria
Sample size was calculated using EPI info 2000 statistical package:- 60 patients diagnosed with LN depending on lab criteria and imaging are submitted for this study
You may qualify if:
- Pts with SLE that have LN in different classes.
- Age between 18-60 yrs.
You may not qualify if:
- Pts with ESRD, manifested cardiac valvular disease, acute infection, history of hepatitis, pts with DM and Cancer.
- Age below 18 yrs\& above 60 yrs
- Pt who refused to contribute in this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (2)
Parikh SV, Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis. 2020 Aug;76(2):265-281. doi: 10.1053/j.ajkd.2019.10.017. Epub 2020 Mar 24.
PMID: 32220510BACKGROUNDYap DYH, Chan TM. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int J Mol Sci. 2019 Dec 10;20(24):6231. doi: 10.3390/ijms20246231.
PMID: 31835612BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- doctor
Study Record Dates
First Submitted
November 12, 2023
First Posted
March 1, 2024
Study Start
March 20, 2024
Primary Completion
November 1, 2024
Study Completion
December 1, 2024
Last Updated
March 1, 2024
Record last verified: 2024-02